|
|
Volumn 2, Issue 3, 2005, Pages 126-127
|
|
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
|
|
Author keywords
Chronic myeloid leukemia; Cytarabine; Imatinib; Interferon ; Pharmacoeconomics
|
|
Indexed keywords
ALPHA INTERFERON;
CYTARABINE;
HYDROXYUREA;
IMATINIB;
PROTEIN TYROSINE KINASE INHIBITOR;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG RESPONSE;
DRUG SUBSTITUTION;
DRUG USE;
HEALTH CARE AVAILABILITY;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
HUMAN;
LIFESPAN;
LOW DRUG DOSE;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
PROSPECTIVE PAYMENT;
SHORT SURVEY;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
COST-BENEFIT ANALYSIS;
HUMANS;
INTERFERON-ALPHA;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PYRIMIDINES;
QUALITY-ADJUSTED LIFE YEARS;
RETROSPECTIVE STUDIES;
SURVIVAL ANALYSIS;
|
|
EID: 20444461685
PISSN: 17434254
EISSN: None
Source Type: Journal
DOI: 10.1038/ncponc0110 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (2)
|
